The DOI matches its Crossref record.
Eletriptan in acute migraine: A double-blind, placebo-controlled comparison to sumatriptan
Abstract
OBJECTIVE: To compare the efficacy, safety, and tolerability of oral eletriptan (20 mg, 40 mg, and 80 mg) with that of oral sumatriptan (100 mg) and placebo for the acute treatment of migraine. BACKGROUND: Eletriptan is a potent and selective agonist at human recombinant 5HT1B/1D receptors, with efficacy in animal models that predict antimigraine activity. In healthy volunteers, the pharmacokinetics of eletriptan are characterized by linear and rapid oral absorption. METHODS: Randomized, double-blind, parallel-group study conducted in 857 outpatients with a diagnosis of migraine according to the International Headache Society (IHS) criteria. Of these, 692 took study medication for one acute migraine attack and provided on-drug efficacy data. Subjects received either placebo, 100 mg of sumatriptan or 20 mg, 40 mg, or 80 mg of eletriptan for the treatment of an acute migraine attack. The primary endpoint was the percentage of patients with a headache response (improvement in pain intensity from moderate or severe to mild or none) at 2 hours after treatment. RESULTS: At the primary endpoint (2 hours after dosing), headache response rates were 24% (30/126) for placebo; 55% (63/115) for sumatriptan, 100 mg; 54% (70/129) for eletriptan, 20 mg; 65% (76/117) for eletriptan, 40 mg; and 77% (91/118) for eletriptan, 80 mg. There was a difference compared with placebo (p<0.001) for all doses of eletriptan, and at 2 hours there was a difference between sumatriptan, 100 mg, and eletriptan, 80 mg (p<0.001). Headache-free rates at 2 hours were superior to placebo (6%; p<0.001) for both the 80-mg dose of eletriptan (37%) and the 40-mg dose (29%), with the 80-mg dose also being superior to 100 mg of sumatriptan (23%; p<0.05). Eletriptan and sumatriptan were well tolerated, and the majority of adverse events were mild or moderate in intensity and transient. CONCLUSION: In this placebo-controlled trial, eletriptan, at selected doses, demonstrated superior efficacy, onset of action and patient acceptability in the acute treatment of migraine when compared with oral sumatriptan and placebo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The interrelations of migraine, vertigo, and migrainous vertigo
Neuhauser, H., Leopold, M., von Brevern, M., Arnold, G., & Lempert, T. (2001) · Neurology · doi:10.1212/wnl.56.4.436 · Cited by 792
Ferrari, M., Goadsby, P., Roon, K., & Lipton, R. (2002) · Cephalalgia · doi:10.1046/j.1468-2982.2002.00404.x · Cited by 605
Self-citationDodick, D., Lipton, R. B., Martin, V., Papademetriou, V., Rosamond, W., MaassenVanDenBrink, A., Loutfi, H., Welch, K. M., Goadsby, P. J., Hahn, S., et al. (2004) · Headache: The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2004.04078.x · Cited by 351
Self-citationHofman, K., Liu, N., & Manolikakes, G. (2018) · Chemistry – A European Journal · doi:10.1002/chem.201705470 · Cited by 283
A systematic review of adverse events in placebo groups of anti-migraine clinical trials
Amanzio, M., Corazzini, L. L., Vase, L., & Benedetti, F. (2009) · Pain · doi:10.1016/j.pain.2009.07.010 · Cited by 232
Metadata
- Authors
- Goadsby, P. J., Ferrari, M. D., Olesen, J., Stovner, L. J., Senard, J. M., Jackson, N. C., & Poole, P. H.
- Venue
- Neurology
- Published
- 2000-01-11
- Volume
- 54
- Issue
- 1
- Pages
- 156-156
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W48338217
- Cited by
- 188
- References
- 0
- FWCI
- 17.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Eletriptan in acute migraine: A double-blind, placebo-controlled comparison to sumatriptan. https://app.cochat.ai/papers/10.1212/wnl.54.1.156
- The paper
- Goadsby, P. J., Ferrari, M. D., Olesen, J., Stovner, L. J., Senard, J. M., Jackson, N. C., & Poole, P. H. (2000). Eletriptan in acute migraine: A double-blind, placebo-controlled comparison to sumatriptan. Neurology. https://doi.org/10.1212/wnl.54.1.156
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.